Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Genentech's glyco-engineered antibody to succeed Rituxan.

Literature DB >> 24406911

Genentech's glyco-engineered antibody to succeed Rituxan.

Mark Ratner.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2014 PMID： 24406911 DOI： 10.1038/nbt0114-6b

Source DB: PubMed Journal: Nat Biotechnol ISSN： 1087-0156 Impact factor: 54.908

× No keyword cloud information.

2 in total

1. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity.

Authors: P Umaña; J Jean-Mairet; R Moudry; H Amstutz; J E Bailey
Journal: Nat Biotechnol Date: 1999-02 Impact factor: 54.908

2. FDA moves on breakthrough therapies.

Authors: Jeffrey L Fox
Journal: Nat Biotechnol Date: 2013-05 Impact factor: 54.908

2 in total

18 in total

Review 1. Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability.

Authors: Satish K Singh; Donna L Luisi; Roger H Pak
Journal: Pharm Res Date: 2015-05-19 Impact factor: 4.200

2. No added sugar: antibody makers find an upside to 'no fucose'.

Authors: Ken Garber
Journal: Nat Biotechnol Date: 2018-11-09 Impact factor: 54.908

3. Animal Cell Expression Systems.

Authors: M Butler; U Reichl
Journal: Adv Biochem Eng Biotechnol Date: 2021 Impact factor: 2.635

Review 4. Drug discovery and therapeutic delivery for the treatment of B and T cell tumors.

Authors: Regan Stephenson; Ankur Singh
Journal: Adv Drug Deliv Rev Date: 2017-06-15 Impact factor: 15.470

Review 5. Analytical comparability study of recombinant monoclonal antibody therapeutics.

Authors: Alexandre Ambrogelly; Stephen Gozo; Amit Katiyar; Shara Dellatore; Yune Kune; Ram Bhat; Joanne Sun; Ning Li; Dongdong Wang; Christine Nowak; Alyssa Neill; Gomathinayagam Ponniah; Cory King; Bruce Mason; Alain Beck; Hongcheng Liu
Journal: MAbs Date: 2018-03-20 Impact factor: 5.857

Genentech's glyco-engineered antibody to succeed Rituxan.

1. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity.

2. FDA moves on breakthrough therapies.

Review 1. Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability.

2. No added sugar: antibody makers find an upside to 'no fucose'.

3. Animal Cell Expression Systems.

Review 4. Drug discovery and therapeutic delivery for the treatment of B and T cell tumors.

Review 5. Analytical comparability study of recombinant monoclonal antibody therapeutics.

6. Glycoengineering of antibody (Herceptin) through yeast expression and in vitro enzymatic glycosylation.

Review 7. Three major uncertainties in the antibody therapy of cancer.

Review 8. Prospects for engineering HIV-specific antibodies for enhanced effector function and half-life.

Review 9. Glycoengineering of Antibodies for Modulating Functions.

10. Site-Specific N-Glycosylation of Recombinant Pentameric and Hexameric Human IgM.